Clinical Trial Detail

NCT ID NCT02257567
Title A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

diffuse large B-cell lymphoma

follicular lymphoma

Therapies

Bendamustine + Rituximab

Polatuzumab vedotin-piiq

Obinutuzumab

Age Groups: adult

No variant requirements are available.